Refereed journal article or data article (A1)
18F-Labeled Modified Porous Silicon Particles for Investigation of Drug Delivery Carrier Distribution in Vivo with Positron Emission Tomography
List of Authors: Sarparanta M, Mäkilä E, Heikkilä T, Salonen J, Kukk E, Lehto V, Santos HA, Hirvonen J, Airaksinen AJ
Publisher: American Chemical Society
Publication year: 2011
Journal: Molecular Pharmaceutics
Journal name in source: Molecular Pharmaceutics; Mol. Pharmaceutics
Journal acronym: MOL PHARMACEUTICS
Number in series: 5
Volume number: 8
Issue number: 5
Start page: 1799
End page: 1806
Number of pages: 8
ISSN: 1543-8384
DOI: http://dx.doi.org/10.1021/mp2001654
URL: http://dx.doi.org/10.1021/mp2001654
Abstract
Because of its biocompatibility and ability to accommodate a variety of payloads from poorly soluble drugs to biomolecules, porous silicon (PSi) is a lucrative material for the development of carriers for particle-mediated drug delivery. We report a successful direct one-step 18F-radiolabeling of three types of PSi microparticles, thermally hydrocarbonized THCPSi, thermally oxidized TOPSi, and thermally carbonized TCPSi for the investigation of their biodistribution in vivo with positron emission tomography as part of their evaluation as carriers for particle-mediated drug delivery. FTIR and XPS characterization of the PSi materials after carrier-added 18F/19F-radiolabeling reveals that depending on the material the 18F-labeling is likely to be accomplished either by substitution for surface silyl hydrogen or silyl fluoride or by nucleophilic attack of 18F? to Si?O?Si bridges. With the selected 18F-radiolabeling method, good to excellent in vitro radiolabel stability in simulated gastric and intestinal fluids and in plasma is achieved for all the particle types studied. Finally, a preliminary evaluation of 18F-THCPSi microparticle biodistribution in the rat gastrointestinal tract after oral administration is reported, illustrating the utility of using 18F-radiolabeled PSi as imaging probes for PSi-based drug delivery carrier distribution in vivo.\nBecause of its biocompatibility and ability to accommodate a variety of payloads from poorly soluble drugs to biomolecules, porous silicon (PSi) is a lucrative material for the development of carriers for particle-mediated drug delivery. We report a successful direct one-step 18F-radiolabeling of three types of PSi microparticles, thermally hydrocarbonized THCPSi, thermally oxidized TOPSi, and thermally carbonized TCPSi for the investigation of their biodistribution in vivo with positron emission tomography as part of their evaluation as carriers for particle-mediated drug delivery. FTIR and XPS characterization of the PSi materials after carrier-added 18F/19F-radiolabeling reveals that depending on the material the 18F-labeling is likely to be accomplished either by substitution for surface silyl hydrogen or silyl fluoride or by nucleophilic attack of 18F? to Si?O?Si bridges. With the selected 18F-radiolabeling method, good to excellent in vitro radiolabel stability in simulated gastric and intestinal fluids and in plasma is achieved for all the particle types studied. Finally, a preliminary evaluation of 18F-THCPSi microparticle biodistribution in the rat gastrointestinal tract after oral administration is reported, illustrating the utility of using 18F-radiolabeled PSi as imaging probes for PSi-based drug delivery carrier distribution in vivo.
Because of its biocompatibility and ability to accommodate a variety of payloads from poorly soluble drugs to biomolecules, porous silicon (PSi) is a lucrative material for the development of carriers for particle-mediated drug delivery. We report a successful direct one-step 18F-radiolabeling of three types of PSi microparticles, thermally hydrocarbonized THCPSi, thermally oxidized TOPSi, and thermally carbonized TCPSi for the investigation of their biodistribution in vivo with positron emission tomography as part of their evaluation as carriers for particle-mediated drug delivery. FTIR and XPS characterization of the PSi materials after carrier-added 18F/19F-radiolabeling reveals that depending on the material the 18F-labeling is likely to be accomplished either by substitution for surface silyl hydrogen or silyl fluoride or by nucleophilic attack of 18F? to Si?O?Si bridges. With the selected 18F-radiolabeling method, good to excellent in vitro radiolabel stability in simulated gastric and intestinal fluids and in plasma is achieved for all the particle types studied. Finally, a preliminary evaluation of 18F-THCPSi microparticle biodistribution in the rat gastrointestinal tract after oral administration is reported, illustrating the utility of using 18F-radiolabeled PSi as imaging probes for PSi-based drug delivery carrier distribution in vivo.\nBecause of its biocompatibility and ability to accommodate a variety of payloads from poorly soluble drugs to biomolecules, porous silicon (PSi) is a lucrative material for the development of carriers for particle-mediated drug delivery. We report a successful direct one-step 18F-radiolabeling of three types of PSi microparticles, thermally hydrocarbonized THCPSi, thermally oxidized TOPSi, and thermally carbonized TCPSi for the investigation of their biodistribution in vivo with positron emission tomography as part of their evaluation as carriers for particle-mediated drug delivery. FTIR and XPS characterization of the PSi materials after carrier-added 18F/19F-radiolabeling reveals that depending on the material the 18F-labeling is likely to be accomplished either by substitution for surface silyl hydrogen or silyl fluoride or by nucleophilic attack of 18F? to Si?O?Si bridges. With the selected 18F-radiolabeling method, good to excellent in vitro radiolabel stability in simulated gastric and intestinal fluids and in plasma is achieved for all the particle types studied. Finally, a preliminary evaluation of 18F-THCPSi microparticle biodistribution in the rat gastrointestinal tract after oral administration is reported, illustrating the utility of using 18F-radiolabeled PSi as imaging probes for PSi-based drug delivery carrier distribution in vivo.